This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The continued evolution of treatment protocols and ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...

Atossa Therapeutics, Inc. has provided a shareholder update highlighting significant progress in their clinical programs, particularly with their therapy (Z)-endoxifen for breast cancer prevention ...

Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00. Farzin Haque has given his Buy rating due to a combination ...

Investors and stakeholders are advised to monitor Summit Therapeutics’ progress closely, especially with upcoming clinical trial results and expansion plans in the oncology market. The ...

President Biden penned a letter ahead of his farewell address on Wednesday night, highlighting his accomplishments over four years and calling on Americans to build on his progress. Biden outlined ...

The company's clinical progress has been marked by several key achievements. In the FT819 program targeting SLE, Fate Therapeutics has reported consistent and robust peripheral CD19+ B cell depletion ...

Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. Teoxane ...